Neuroprotective activity of novel phenanthrene derivative from Grewia tiliaefolia by in vitro and in silico studies DOI Creative Commons
Ankita Rajput,

Palvi Sharma,

Nitish Kumar

et al.

Scientific Reports, Journal Year: 2023, Volume and Issue: 13(1)

Published: Feb. 10, 2023

Abstract Medicinal plants possess range of phytochemicals accountable for their diverse biological activities. Presently, such compounds have been isolated from medicinal plants, characterized and evaluated pharmacological potential. In the present study, efforts made to isolate compound(s) Grewia tiliaefolia Vahl., plant known its ameliorative effect on brain related diseases as anxiety, depression, cognitive disorders Parkinson’s disease. Plant extract was subjected isolation using column chromatography compound by NMR FTIR LCMS. The novel with IUPAC name is propyl 3-hydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylate, designated A-1 has not reported before. further antioxidant potential in vitro assays (2,2-diphenyl-1-picryl-hydrazyl-hydrate, DPPH assay reducing power assay, RPA). Also, Acetylcholinesterase (AChE) inhibitory analysed. Results showed that exhibited significantly higher activity both RPA compared extract. case AChE again, shown silico study conducted predict action proteins playing crucial role neurological neurodegenerative gamma amino butyric acid (GABA) receptor glutamate α amino-3-hydroxyl-5-methyl-4-isoxazolepropionic (Glu AMPA) epilepsy enzyme Alzheimer’s diseases. interaction following order: > GABA Glu AMPA receptor. Further, molecular dynamic simulations ADME studies revealed yielded good results all parameters hence can relieve like symptoms.

Language: Английский

Exploration of 1,2,3-triazole linked benzenesulfonamide derivatives as isoform selective inhibitors of human carbonic anhydrase DOI Open Access

Chnar Kakakhan,

Cüneyt Türkeş, Özcan Güleç

et al.

Bioorganic & Medicinal Chemistry, Journal Year: 2022, Volume and Issue: 77, P. 117111 - 117111

Published: Nov. 29, 2022

Language: Английский

Citations

81

Discovery of novel benzenesulfonamides incorporating 1,2,3-triazole scaffold as carbonic anhydrase I, II, IX, and XII inhibitors DOI

Aida Buza,

Cüneyt Türkeş, Mustafa Arslan

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 239, P. 124232 - 124232

Published: March 29, 2023

Language: Английский

Citations

68

Novel beta-lactam substituted benzenesulfonamides: in vitro enzyme inhibition, cytotoxic activity and in silico interactions DOI
Özcan Güleç, Cüneyt Türkeş, Mustafa Arslan

et al.

Journal of Biomolecular Structure and Dynamics, Journal Year: 2023, Volume and Issue: 42(12), P. 6359 - 6377

Published: Aug. 4, 2023

In this study, a library of twelve beta-lactam-substituted benzenesulfonamides (

Language: Английский

Citations

55

Bioactivity, cytotoxicity, and molecular modeling studies of novel sulfonamides as dual inhibitors of carbonic anhydrases and acetylcholinesterase DOI
Özcan Güleç, Cüneyt Türkeş, Mustafa Arslan

et al.

Journal of Molecular Liquids, Journal Year: 2024, Volume and Issue: 410, P. 125558 - 125558

Published: July 18, 2024

Language: Английский

Citations

26

Synthesis and biological studies of pyrimidine derivatives targeting metabolic enzymes DOI Creative Commons
Elif Korkusuz, Yusuf Sert,

Seher Arslan

et al.

Archiv der Pharmazie, Journal Year: 2024, Volume and Issue: 357(8)

Published: May 21, 2024

Abstract Novel synthesized pyrimidine derivatives were investigated against carbonic anhydrase isoenzymes I and II (hCA II), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), α‐glycosidase, aldose reductase (AR) enzymes associated with some common diseases such as epilepsy, glaucoma, Alzheimer's disease, diabetes, neuropathy. When the results examined, novel found to have effective inhibition abilities toward metabolic enzymes. IC 50 values K i calculated for each derivative compared positive controls. The exhibited in range of 39.16 ± 7.70–144.62 26.98 nM hCA I, 18.21 3.66–136.35 21.48 II, which is different pathological physiological processes, 33.15 4.85–52.98 19.86 on AChE, 31.96 8.24–69.57 21.27 BChE. Also, determined 17.37 1.11–253.88 39.91 α‐glycosidase 648.82 53.74–1902.58 98.90 AR Within scope study, types evaluated.

Language: Английский

Citations

22

Using deep learning and molecular dynamics simulations to unravel the regulation mechanism of peptides as noncompetitive inhibitor of xanthine oxidase DOI Creative Commons
Yi He, Kaifeng Liu,

Fuyan Cao

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Jan. 2, 2024

Abstract Xanthine oxidase (XO) is a crucial enzyme in the development of hyperuricemia and gout. This study focuses on LWM ALPM, two food-derived inhibitors XO. We used molecular docking to obtain three systems then conducted 200 ns dynamics simulations for Apo, LWM, ALPM systems. The results reveal stronger binding affinity peptide XO, potentially due increased hydrogen bond formation. Notable changes were observed XO tunnel upon inhibitor binding, particularly with which showed thinner, longer, more twisted configuration compared ALPM. highlights importance residue F914 allosteric pathway. Methodologically, we utilized perturbed response scan (PRS) based Python, enhancing tools MD analysis. These findings deepen our understanding anti-XO could inform food-based therapeutics reducing uric acid levels minimal side effects.

Language: Английский

Citations

16

Insights into Manganese Superoxide Dismutase and Human Diseases DOI Open Access
Mengfan Liu, Xueyang Sun,

Boya Chen

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(24), P. 15893 - 15893

Published: Dec. 14, 2022

Redox equilibria and the modulation of redox signalling play crucial roles in physiological processes. Overproduction reactive oxygen species (ROS) disrupts body's antioxidant defence, compromising homeostasis increasing oxidative stress, leading to development several diseases. Manganese superoxide dismutase (MnSOD) is a principal enzyme that protects cells from damage by converting anion radicals hydrogen peroxide mitochondria. Systematic studies have demonstrated MnSOD plays an indispensable role multiple This review focuses on preclinical evidence describes mechanisms diseases accompanied with imbalanced status, including fibrotic diseases, inflammation, diabetes, vascular neurodegenerative cancer. The potential therapeutic effects activators mimetics are also discussed. Targeting this specific radical scavenger may be clinically beneficial strategy, understanding provide positive insight into preventing treating related

Language: Английский

Citations

67

Synthesis and characterization of novel acyl hydrazones derived from vanillin as potential aldose reductase inhibitors DOI
Yeliz Demir, Feyzi Sinan Tokalı, Erbay Kalay

et al.

Molecular Diversity, Journal Year: 2022, Volume and Issue: 27(4), P. 1713 - 1733

Published: Sept. 14, 2022

Language: Английский

Citations

57

Novel bis-ureido-substituted sulfaguanidines and sulfisoxazoles as carbonic anhydrase and acetylcholinesterase inhibitors DOI
Nebih Lolak, Süleyman Akocak, Mustafa Durgun

et al.

Molecular Diversity, Journal Year: 2022, Volume and Issue: 27(4), P. 1735 - 1749

Published: Sept. 22, 2022

Language: Английский

Citations

49

Isolation of Some Phenolic Compounds from Plantago subulata L. and Determination of Their Antidiabetic, Anticholinesterase, Antiepileptic and Antioxidant Activity DOI
Muhammet Serhat Özaslan, Rüya Sağlamtaş, Yeliz Demir

et al.

Chemistry & Biodiversity, Journal Year: 2022, Volume and Issue: 19(8)

Published: July 7, 2022

Abstract In the current study, some phenolic compounds, including acteoside, isoacteoside, echinacoside, and arenarioside purified characterized from Plantago subulata . These compounds were tested for its antioxidant potential, Fe 3+ Cu 2+ reductive ability chelating effects. The inhibitory effects of isolated towards human carbonic anhydrase I II isoenzymes (hCA hCA II), butyrylcholinesterase (BChE) acetylcholinesterase (AChE), aldose reductase (AR) α‐glycosidase (α‐gly). K i values found these in range 0.24±0.05–1.38±0.34 μM against I, 0.194±0.018–1.03±0.06 II, 0.043±0.01–0.154±0.02 AChE, 3.92±1.08–11.93±4.45 BChE, 0.082±0.0008–1.68±0.42 AR, 6.93±2.74–17.17±6.70 α‐glycosidase. As a result, displayed inhibition studied all metabolic enzymes. They are promising candidates treating disorders like Alzheimer's disease, diabetes mellitus, glaucoma, leukemia, epilepsy.

Language: Английский

Citations

48